Compounds > dmp 450
Page last updated: 2024-12-08

dmp 450

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DMP 450: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID154044
CHEMBL ID223824
SCHEMBL ID3455127
MeSH IDM0262000

Synonyms (27)

Synonym
bdbm151
chembl223824 ,
174391-92-5
mozenavir (inn)
D05538
mozenavir (*bismesylate salt*)
dmp450
xm412
dmp-450
(4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one
dmp 450
[4r-(4.alpha.,5.alpha.,6.beta.,7.beta.)]-1,3- bis[(3-aminophenyl)methyl]-hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2h-1,3-diazepin-2-one dimethanesulfonate
[4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone
dmp450(inhibitor of dupont merck)
DB02102
mozenavir
1DMP
mozenavir [inn]
64oo8946er ,
(4r,5s,6s,7r)-1,3-bis(3-aminobenzyl)-4,7-dibenzylhexahydro-5,6-dihydroxy-2h-1,3-diazepin-2-one
unii-64oo8946er
SCHEMBL3455127
DTXSID40169822
(4r,5s,6s,7r)-1,3-bis(3-aminobenzyl)-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one
Q63390512
KYRSNWPSSXSNEP-ZRTHHSRSSA-N
2h-1,3-diazepin-2-one, 1,3-bis[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-, (4r,5s,6s,7r)-

Research Excerpts

Overview

DMP 450 is a significant advance within the cyclic urea class of HIV protease inhibitors due to its exceptional oral bioavailability.

ExcerptReferenceRelevance
"DMP 450 is a significant advance within the cyclic urea class of HIV protease inhibitors due to its exceptional oral bioavailability. "( Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
Aldrich, PE; Bacheler, LT; Chang, CH; Erickson-Viitanen, S; Eyermann, CJ; Garber, S; Grubb, M; Hodge, CN; Jackson, DA; Jadhav, PK; Korant, B; Lam, PY; Maurin, MB; Meek, JL; Otto, MJ; Rayner, MM; Reid, C; Sharpe, TR; Shum, L; Winslow, DL, 1996)		1.94

Bioavailability

ExcerptReferenceRelevance
" The small size probably contributes to the observed good oral bioavailability in animals."( Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
Aldrich, PE; Bacheler, LT; Chang, CH; Confalone, PN; Daneker, WF; DeLucca, GV; Emmett, G; Eyermann, CJ; Han, Q; Hodge, CN; Holler, ER; Jadhav, PK; Klabe, RM; Kornhauser, DM; Lam, PY; Li, L; Li, R; Markwalder, JA; McHugh, RJ; Rayner, MM; Ru, Y; Seitz, SP; Sharpe, TR; Shum, L; Winslow, DL, 1996)		0.29
"Effective HIV protease inhibitors must combine potency towards wild-type and mutant variants of HIV with oral bioavailability such that drug levels in relevant tissues continuously exceed that required for inhibition of virus replication."( Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
Aldrich, PE; Bacheler, LT; Chang, CH; Erickson-Viitanen, S; Eyermann, CJ; Garber, S; Grubb, M; Hodge, CN; Jackson, DA; Jadhav, PK; Korant, B; Lam, PY; Maurin, MB; Meek, JL; Otto, MJ; Rayner, MM; Reid, C; Sharpe, TR; Shum, L; Winslow, DL, 1996)		0.49
" Using this approach several very potent (IC90 11 nM) and orally bioavailable (F% 93-100%) compounds were discovered (21, 22)."( Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
Bacheler, LT; Cordova, B; De Lucca, GV; Erickson-Viitanen, S; Garber, S; Kim, UT; Klabe, RM; Ko, SS; Lam, GN; Liang, J; Logue, KA; Trainor, GL; Wright, MR, 1998)		0.3
" The ultimate success of DMP 850 and DMP 851 in clinical trials might depend on achieving or exceeding the oral bioavailability seen in dog."( Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR, 1998)		0.3
" Several of these compounds were examined for oral bioavailability in the rat or the dog at 10 mg/kg."( Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
De Lucca, GV; De Lucca, I; Liang, J, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.00030.00030.00030.0003AID977610
Chain B, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.00030.00030.00030.0003AID977610
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (BRU ISOLATE)Ki0.00030.00000.08283.3000AID1795214
Gag-Pol polyproteinHIV-1 M:B_HXB2RKi0.00030.00000.51449.0000AID1795292
Protease Human immunodeficiency virus 1Ki0.00030.00000.04433.1000AID160292; AID160316; AID160454; AID160458; AID160474; AID162710; AID163483; AID82912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thromboxane-A synthaseRattus norvegicus (Norway rat)IC90 (µMol)0.12500.01040.07030.1250AID210277
Protease Human immunodeficiency virus 1IC90 (µMol)0.12250.00200.67847.3000AID105206; AID210277
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID235093Resistance of constructed mutant 461/47V/50V virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID235095Resistance of constructed mutant 82A virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID14284Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
AID160292Inhibition of HIV-1 protease1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
AID235099Resistance of constructed mutant MK639 virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID104232The antiviral potency (IC90) was assessed by measuring their effect on the accumulation of viral RNA transcripts on HIV-1 RF infected MT-2 cells1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
AID160316Binding affinity to inhibit the purified wild-type HIV-1 Protease1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID105206Inhibitory concentration against accumulation of viral p24 antigen following infection of MT-4 cells1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID235097Resistance of constructed mutant 84V virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID163483Binding affinity for HIV-1 protease enzyme was measured by using fluorescent peptide substrate1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
AID82610Antiviral activity against mutant virus HIV-1 mutant (84V) strain1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
AID82609Antiviral activity against indinavir virus (HIV-1 mutated at 10R/63P/71V/82F/84V and resistant to indinavir)1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
AID104226Antiviral potency evaluated by measuring accumulation of viral RNA transcripts 3 days after infection of MT-2 cells with HIV-1 RF1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
AID25130Half life (10 mg/kg, intravenously) determined by administering intravenously in dogs1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID19831Partition coefficient (logP) (HPLC)1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID18200Oral bioavailability in dog (dose 10 mg/kg)1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID104224Antiviral activity by measuring its effect on the accumulation of viral RNA transcripts on infection of MT-2 cells with HIV-1 RF.1999Journal of medicinal chemistry, Jan-14, Volume: 42, Issue:1
Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
AID82611Antiviral activity against mutant virus HIV-1 mutant (84V/82F) strain1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
AID160458Inhibition of HIV protease, measured by assaying the cleavage of a fluorescent peptide substrate using HPLC1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
AID210277Inhibition of HIV RNA synthesis in T-cell line1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID22996Apparent volume of distribution of compound (10 mg/kg, intravenously) in dogs1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID82612Antiviral activity against ritonavir virus (HIV-1 mutated at 46I/63P/71V/82F/84V and resistant to ritonavir)1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
AID235098Resistance of constructed mutant ABT538 virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID15511Clearance (10 mg/kg, intravenously) in dog plasma1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID227243Whole cell antiviral activity.1998Bioorganic & medicinal chemistry letters, Apr-07, Volume: 8, Issue:7
The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
AID14055Maximum concentration (10 mg/kg, orally) in plasma of dogs1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID25131Half life (10 mg/kg, orally) determined by administering intravenously in dog plasma1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID235096Resistance of constructed mutant 82F virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID14635The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.1999Journal of medicinal chemistry, Jan-14, Volume: 42, Issue:1
Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
AID82912HIV protease inhibition.1998Bioorganic & medicinal chemistry letters, Apr-07, Volume: 8, Issue:7
The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
AID162710Affinity against HIV protease1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID235094Resistance of constructed mutant 48V/90M virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID104229Concentration which reduced the concentration of HIV viral RNA by 90% from the level measured in an untreated infected culture1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
AID282343Inhibition of HIV1 protease2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors.
AID160474Inhibitory activity against HIV protease1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
AID160454Inhibition constant of HIV protease inhibitors1999Journal of medicinal chemistry, Jan-14, Volume: 42, Issue:1
Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1996Chemistry & biology, Apr, Volume: 3, Issue:4
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
AID1811Experimentally measured binding affinity data derived from PDB1996Chemistry & biology, Apr, Volume: 3, Issue:4
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
AID1799449Protease Inhibtion Assay from Article 10.1016/s1074-5521(98)90117-x: \\Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.\\1998Chemistry & biology, Oct, Volume: 5, Issue:10
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
AID1795292Protease Inhibition Assay from Article 10.1021/jm9803626: \\Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.\\1999Journal of medicinal chemistry, Jan-14, Volume: 42, Issue:1
Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
AID1795214Protease Inhibition Assay from Article 10.1021/jm9602571: \\Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.\\1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's18 (78.26)18.2507
2000's4 (17.39)29.6817
2010's1 (4.35)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.96 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		210amino-acid anion
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		1.9910alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		10.11140isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
lactose
Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.		210lactose
acetonitrile
acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.		1.9910aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		1.9910indazole
tungsten
Tungsten: A metallic element with the atomic symbol W, atomic number 74, and atomic weight 183.85. It is used in many manufacturing applications, including increasing the hardness, toughness, and tensile strength of steel; manufacture of filaments for incandescent light bulbs; and in contact points for automotive and electrical apparatus.		2.0110chromium group element atommicronutrient
dimethylacetamide
hallucinogen : Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking.. N,N-dimethylacetamide : A member of the class of acetamides that is acetamide in which the hydrogens attached to the N atom have been replaced by two methyl groups respectively. Metabolite observed in cancer metabolism.		210acetamides;
monocarboxylic acid amide		human metabolite
potassium phosphate
potassium phosphate: used in dental materials and to treat hypophosphatemia; RN given refers to cpd with unspecified MF. tripotassium phosphate : An inorganic potassium salt that is the tripotassium salt of phosphoric acid.		1.9910inorganic phosphate salt;
inorganic potassium salt
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		1.9910acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nelfinavir
Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.		2.730aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
amprenavir
[no description available]		2.9140carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
dmp 323
(4R,5S,6S,7R)-4,7-dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one : A 1,3-diazepanone ring with two 4-(hydroxymethyl)benzyl groups as substituents at positions N-1 and N-4, two benzyl groups at C-4 and C-7, and two hydroxy groups at C-5 and C-6 respectively.		10.18150diazepanone;
ureas		anti-HIV agent;
metabolite
hexacarbonyltungsten
hexacarbonyltungsten: C6-O6-W		2.0110
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		3.09501,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
xv 638
XV638 : A member of the class of diazepanones that is 1,3-diazepane which is substituted by a 3-(1,3-thiazol-2-ylcarbamoyl)benzyl group at positions 1 and 3, oxo group at position 2, hydroxy groups at positions 5S and 6S, and benzyl groups at positions 4R and 7R. It is a potent HIV-1 protease inhibitor.		2.91401,3-thiazoles;
benzamides;
diazepanone;
diol;
secondary alcohol;
secondary carboxamide;
ureas		HIV protease inhibitor
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		2.6830L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
xk 263
[no description available]		2.9140
dmp 850
DMP 850: structure in first source		2.420
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		2.9140dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
tipranavir
tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.		2.0210sulfonamideantiviral drug;
HIV protease inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.3920
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.6930
HIV Coinfection
[description not available]		01.9910
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		01.9910